Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2003
03/06/2003US20030045513 Solution comprising: a) water; b) propylene glycol; c) 2-propanol; and d) hydrocortisone; dispensing solution into an external ear canal and contacting a wick with the solution to expand the wick within the canal
03/06/2003US20030045512 Androstanecarbothioic acid derivatives, especially esterified with thazol-5-ylcarboxylic acid; formulation for administration by inhalation
03/06/2003US20030045508 Phosphoramidates
03/06/2003US20030045505 Oligosaccharide having at least a D-galactose unit bound by an alpha (1-6) bond with a sucrose unit; second component is a molecule positively charged at physiological pH and that promotes pinocytosis or membrane penetration
03/06/2003US20030045502 Oral intake solution
03/06/2003US20030045484 Crystallizing amorphous daptomycin from a crystallization solution comprising a cation from a salt, a buffer, an organic precipitant, and a low molecular weight alcohol.
03/06/2003US20030045481 Use of specific amino acids reduces or prevents coloration attributable to a saccharide stabilizer; especially useful in pharmacologically active proteinaceous compositions
03/06/2003US20030045465 RTransport polymer comprising a linear or branched peptide having 10-300 amino acid residues, having from about 5 to 100% histidine residues; drug delivery, especially gene therapy and cancer chemotherapy
03/06/2003US20030045461 Composition and methods of esterified nitroxides gated with carboxylic acids
03/06/2003US20030045454 Sustained release formulation
03/06/2003US20030044983 Nucleic acid transfer complexes
03/06/2003US20030044961 Compositions for transferring active compounds in a cell-specific manner
03/06/2003US20030044528 Spraying a solution wherein a poorly soluble drug is dissolved in a plasticizer, and an aqueous solution and/or water dispersion of a water-soluble polymer, from nozzle outlets simultaneously and separately.
03/06/2003US20030044514 Using supercritical fluids to infuse therapeutic on a medical device
03/06/2003US20030044479 Process for the production of pure guar meal
03/06/2003US20030044478 Burnet extract
03/06/2003US20030044476 Use for its anti-elastase and anti-inflammatory activity on human gums; chewing gum or gel for treating gingivitis
03/06/2003US20030044474 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
03/06/2003US20030044473 Blood type dietary supplements
03/06/2003US20030044469 Retinol or retinoic acid encapsulated in a chitosan matrix, particularly in combination with carboxymethyl cellulose, to form microcapsules with improved stability of the retinol
03/06/2003US20030044468 Shaping polymeric precursors by inducing thermal gelation of an aqueous solution thereof and then curing said precursors by crosslinking reactive groups; biomedical uses include drug delivery, microencapsulation, implantation
03/06/2003US20030044467 Gel composition and methods
03/06/2003US20030044466 Oral drug delivery systems where drug is administered with any of specified substances that induce "fed mode" in stomach such as tryptophan dipeptide or cetylpyridinium chloride to prolong retention in stomach; bioavailability
03/06/2003US20030044465 Improving quality of life (QOL) and patient compliance by controlling the in vivo release rate of the drug (2-amino-3-cyano-5-(2-fluorophenyl)-4-methylpyrrole) and also by means of reducing the frequency of taking the drug
03/06/2003US20030044464 Sustained-release, oral pharamaceutical forms of formulation
03/06/2003US20030044463 Sustained release of microcrystalline peptide suspensions
03/06/2003US20030044462 A pharmaceutical composition in solid form also comprising a stabilizer carboxyvinyl polymer to prevent or inhibit the degradation of bupropion hydrochloride
03/06/2003US20030044461 Antitussive/expectorant compositions
03/06/2003US20030044460 Spray drying process control of drying kinetics
03/06/2003US20030044459 A drug forms comprising atorvastatin calcium and a pharmaceutically acceptable carrier, diluent or excipient other than calcium carbonate; treatment of hyperlipidaemia, hypercholesterolaemia
03/06/2003US20030044458 Oral dosage form comprising a therapeutic agent and an adverse-effect agent
03/06/2003US20030044457 Drug delivery device containing oseltamivir and an H1 antagonist
03/06/2003US20030044456 A hydrolysate gelatin is extracted from poultry skins, bones and/or tendons, with an isoelectric point at pH 7-10, treated with acid solution, then hydrolysis; use for food, medicine and cosmetics
03/06/2003US20030044455 Nanogels and their production using liposomes as reactors
03/06/2003US20030044454 Compositions containing liposomes and/or emulsions and process for the preparation thereof
03/06/2003US20030044453 An application to the skin and/or mucosa consisting of active substance solid dispersions in a matrix; reduce skin irritation, efficient drug delivery, improve penetration of hydrophilic medicinal substances through the skin
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030044436 Prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups containing at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic or hydroxyl groups
03/06/2003US20030044435 Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties
03/06/2003US20030044434 Lipophilic pharmaceutically active agent, mixture of diglyceride and monoglyceride in weight ratio of 9:1 to 6:4 wherein glycerides are mono- or di-unsaturated fatty acid esters of glycerol, solvents, surfactants; bioavailability
03/06/2003US20030044433 Method for preparing submicron suspensions with polymorph control
03/06/2003US20030044432 Acne treating composition
03/06/2003US20030044407 Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome or polyplex for systemic administration of a therapeutic or diagnostic agent
03/06/2003US20030044374 Topical composition, topical composition precursor, and methods for manufacturing and using
03/06/2003US20030044362 Method and product for skin lightening
03/06/2003US20030044356 Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
03/06/2003US20030044355 Supplying contrast agent in microbubbles which reradiates ultrasonic frequency; detection
03/06/2003US20030043687 Sprinkling method for preparing powder formulations
03/06/2003US20030042638 Method of solubilizing and encapsulating itraconazole
03/06/2003US20030042435 Quartz schist comprising oxides of silicon, aluminum, and iron
03/06/2003US20030041780 Water dispersible compositions containing natural hydrophilic water-insoluble pigments, methods of preparing same and their use
03/06/2003US20030041602 Process for production of nanoparticles and microparticles by spray freezing into liquid
03/06/2003DE20219662U1 Orally administered sponge-like material, useful as satiation agent or drug carrier, is pretreated by oxidation in aqueous solution to reduce strength and prevent gastrointestinal blockage
03/06/2003CA2485193A1 Stable coated microcapsules
03/06/2003CA2465676A1 Compositions and techniques for localized therapy of restenosis
03/06/2003CA2459974A1 Emu-based formulations for wound treatment related application information
03/06/2003CA2459697A1 Apparatus and method for electroporation of biological samples
03/06/2003CA2458854A1 Helicobacter pylori vaccination
03/06/2003CA2458776A1 Controlled release formulation of clarithromycin or tinidazol
03/06/2003CA2458448A1 Spontaneous emulsions containing cyclosporine
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458394A1 Lipophilic drug compositions
03/06/2003CA2458219A1 Oral rinse for treatment or prevention of bacterial and fungal infection
03/06/2003CA2458217A1 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003CA2458132A1 Compositions comprising negatively charched phospholipids for treatment and/or prevention of macular degeneration and method for its manufacture
03/06/2003CA2457979A1 A delivery system
03/06/2003CA2457955A1 Method for treating bronchial constriction and bronchospasm
03/06/2003CA2457341A1 A new extended release oral dosage form
03/06/2003CA2457339A1 A new extended release oral dosage form
03/06/2003CA2457196A1 Compositions containing itraconazole and their preparation methods
03/06/2003CA2456480A1 A combination of quetiapine and zolmitriptan
03/06/2003CA2456348A1 Platinum complexes and their uses in therapy
03/06/2003CA2451740A1 Composition comprising wenguanguo extracts, methods for preparing same and uses thereof
03/06/2003CA2448760A1 Solid preparation
03/05/2003EP1288264A1 Gelling composition
03/05/2003EP1288222A1 Peptidic compounds selectively binding to P-selectin
03/05/2003EP1288214A1 Paroxetine methanesulfonate
03/05/2003EP1287826A1 A crystalline form of the free base of Amlodipine
03/05/2003EP1287824A1 Member for application of ointment and ointment patch employing the same
03/05/2003EP1287823A1 Pharmaceutical excipient having improved compressibility
03/05/2003EP1287822A2 Mesalazine controlled release oral pharmaceutical compositions
03/05/2003EP1287821A1 Multiparticulate formulations of atorvastatin calcium having a modulated rate of drug release
03/05/2003EP1287820A1 Aerosol compositions
03/05/2003EP1287819A1 Method of coating with antibiotics an object having interconnected microcavities and uses thereof
03/05/2003EP1287818A1 Methods of antibiotic coating of objects having interconnected microcavities and the uses thereof
03/05/2003EP1287817A1 Method of treating uterine leiomyomas and intravaginal drug delivery vehicle for use in such method
03/05/2003EP1287810A1 Hair gel comprising Itaconic acid monoester acrylates copolymer
03/05/2003EP1287747A2 Quiescently frozen ice products
03/05/2003EP1287130A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
03/05/2003EP1287039A1 Amphiphilic macrocyclic derivatives and their analogues
03/05/2003EP1286715A1 Lockout mechanism for aerosol drug delivery devices
03/05/2003EP1286703A2 Methods and compounds for controlled release of recombinant parvovirus vectors
03/05/2003EP1286686A2 Methods for preventing strokes by inducing tolerance to e-selectin
03/05/2003EP1286665A2 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
03/05/2003EP1286663A2 Encapsulating a toxic core within a non-toxic region in an oral dosage form
03/05/2003EP1286662A1 Tablets and methods for modified release of hydrophilic and other active agents
03/05/2003EP1286661A2 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
03/05/2003EP1286660A1 Pharmaceutical composition in liquid form for oral administration of an active principle, with unpleasant, in particular bitter, taste
03/05/2003EP1286659A2 Macromolecular drug complexes and compositions containing the same
03/05/2003EP1286658A2 Y-ifn liquid-droplet aerosol and method
1 ... 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 ... 2991